GlassScriptPhysician profile
Amy E Monrreal
NPI 1134542160
$2,551.71
in general payments reported to CMS, 2019-2025
31 companies · $182 in 2025
The $182 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,164 · 2022: $364 · 2023: $590 · 2024: $251 · 2025: $182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,023.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,022.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $442.56 | 2021-2022 | |
| Hologic Sales and Service, LLC | $269.17 | 2023-2025 | Aptima, Thinprep 2000 Processor |
| Horizon Therapeutics Plc | $260.16 | 2021-2022 | |
| Exeltis, USA INC. | $215.90 | 2023-2025 | Slynd |
| Abbott Laboratories | $158.00 | 2021-2022 | |
| Astellas Pharma US INC | $148.68 | 2023-2025 | Veozah |
| Dexcom, INC. | $138.42 | 2021 | |
| Amneal Pharmaceuticals LLC | $111.98 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $110.97 | 2022-2025 | |
| Corcept Therapeutics | $101.32 | 2021 | |
| Daiichi Sankyo INC. | $71.34 | 2023-2025 | Injectafer |
| Abbvie INC. | $60.88 | 2021-2023 | |
| Lilly USA, LLC | $46.03 | 2021 | |
| Coopersurgical, INC. | $43.29 | 2024 | Paragard T 380a |
| Astrazeneca Pharmaceuticals LP | $41.41 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $38.20 | 2023-2024 | Nexplanon |
| Sanofi-Aventis U.S. LLC | $37.04 | 2021 | |
| Merz North America, INC. | $36.07 | 2022 | |
| Insulet Corporation | $24.62 | 2021 | |
| Mayne Pharma Commercial LLC | $23.74 | 2024 | |
| C. R. Bard, INC. & Subsidiaries | $18.45 | 2023 | Bd Onclarity |
| Lifescan, INC. | $18.31 | 2021 | |
| Sumitomo Pharma America, INC. | $18.04 | 2023 | Myfembree |
| Supernus Pharmaceuticals, INC. | $16.54 | 2025 | Qelbree |
| Sage Therapeutics, LLC | $16.54 | 2025 | Zurzuvae |
| Amgen INC. | $15.09 | 2022 | |
| Ascensia Diabetes Care US INC. | $14.95 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.64 | 2021 | |
| Merck Sharp & Dohme LLC | $14.08 | 2024 | Gardasil 9, Gardasil |
| Antares Pharma, INC. | $13.33 | 2021 | |
| Recordati_rare_diseases_inc. | $11.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Monrreal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.